The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy-Reference-Cited by-同舟云学术

The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy

Published:2010-02 Issue:2 Volume:21 Page:331-334
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gill S.,Carney D.,Ritchie D.,Wolf M.,Westerman D.,Prince H.M.,Januszewicz H.,Seymour J.F.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/21/2/331/923436/mdp297.pdf

Reference11 articles.

1. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine;Yamauchi;Clin Cancer Res,2001

2. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia;Tam;Blood,2008

3. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial;Catovsky;Lancet,2007

4. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia;Eichhorst;Blood,2006

5. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia;Keating;J Clin Oncol,2005

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance;Nature Reviews Cancer;2024-07-24

2. Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation;Immunotherapy;2023-04

3. Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis;Cells;2023-02-07

4. Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms;Leukemia;2022-12-12

5. Managing Waldenström’s macroglobulinemia with BTK inhibitors;Leukemia;2022-11-19